Litigation Details for CELGENE CORPORATION v. MSN LABORATORIES PRIVATE LIMITED (D.N.J. 2022)
✉ Email this page to a colleague
CELGENE CORPORATION v. MSN LABORATORIES PRIVATE LIMITED (D.N.J. 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-04-06 |
| Court | District Court, D. New Jersey | Date Terminated | 2022-06-15 |
| Cause | 35:271 Patent Infringement | Assigned To | Esther Salas |
| Jury Demand | None | Referred To | Michael A. Hammer |
| Patents | 10,555,939; 8,198,262; 8,673,939; 8,735,428; 8,828,427; 9,993,467 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CELGENE CORPORATION v. MSN LABORATORIES PRIVATE LIMITED
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for CELGENE CORPORATION v. MSN LABORATORIES PRIVATE LIMITED (D.N.J. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2022-06-15 | 16 | Order of Dismissal | ; 9,993,467; and 10,555,939. 4. Until expiration of the Patents-in-Suit, MSN, including…this Consent Judgment, the term “Patents-in-Suit” shall mean U.S. Patent Nos. 8,198,262; 8,673,939; 8,735,428…purposes of this action only. Until expiration of the Patents-in-Suit, MSN, including any of its successors and… and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any third party…affirmative defenses and demands pertaining to the Patents-in-Suit are hereby dismissed with prejudice and | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
